Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A investigator-sponsored clinical trial assessing SC451

Next Previous
Trial Profile

A investigator-sponsored clinical trial assessing SC451

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 26 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SC 451 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

  • 12 May 2026 According to Sana Biotechnology media release, continued progress toward starting SC451 Phase 1 trial later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation.
  • 13 Mar 2026 According to Sana Biotechnology media release, Sana Expects to File Investigational New Drug (IND) Application for SC451 in Type 1 Diabetes and Initiate Phase 1 Trial as Early as This Year
  • 17 Feb 2026 According to Sana Biotechnology media release, the company expect to generate initial clinical data for SC451 in the treatment of type 1 diabetes and SG293 in a B-cell related disease, helping us better understand these therapies and creating important value inflection points for the company.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top